87 related articles for article (PubMed ID: 8462201)
21. Nonoprerative management of obstructive jaundice caused by a benign hepatic cyst.
Ogawa M; Kubo S; Uenishi T; Hirohashi K; Tanaka H; Shuto T; Yamamoto T; Takemura S
Osaka City Med J; 2004 Dec; 50(2):95-9. PubMed ID: 15819304
[TBL] [Abstract][Full Text] [Related]
22. [A case of muellerian duct cyst treated with minocycline hydrochloride sclerotherapy under ultrasound control].
Fukui J; Gotou T; Yoshihara H; Sakamoto W; Yasumoto R; Kishimoto T; Maekawa M
Hinyokika Kiyo; 1992 Dec; 38(12):1403-6. PubMed ID: 1288231
[TBL] [Abstract][Full Text] [Related]
23. Reliability of magnetic resonance imaging for measuring the volumetric indices in autosomal-dominant polycystic kidney disease: correlation with hypertension and renal function.
Lee YR; Lee KB
Nephron Clin Pract; 2006; 103(4):c173-80. PubMed ID: 16636585
[TBL] [Abstract][Full Text] [Related]
24. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
[TBL] [Abstract][Full Text] [Related]
25. Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease.
Lawson CR; Doulton TW; MacGregor GA
J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):139-45. PubMed ID: 17094050
[TBL] [Abstract][Full Text] [Related]
26. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
27. Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease.
Seeman T; Dusek J; Vondrák K; Bláhová K; Simková E; Kreisinger J; Dvorák P; Kyncl M; Hríbal Z; Janda J
Physiol Res; 2004; 53(6):629-34. PubMed ID: 15588131
[TBL] [Abstract][Full Text] [Related]
28. Hypertension in autosomal dominant polycystic kidney disease: observational study in 207 patients with a mean follow-up of 107 months.
De Almeida EA; Prata MM
Rev Port Cardiol; 2007 Nov; 26(11):1173-82. PubMed ID: 18297839
[TBL] [Abstract][Full Text] [Related]
29. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease.
Loghman-Adham M; Soto CE; Inagami T; Cassis L
Am J Physiol Renal Physiol; 2004 Oct; 287(4):F775-88. PubMed ID: 15187005
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
31. Experience with autosomal dominant polycystic kidney disease in patients before and after renal transplantation: a 7-year observation.
Sulikowski T; Tejchman K; Zietek Z; Rózański J; Domański L; Kamiński M; Sieńko J; Romanowski M; Nowacki M; Pabisiak K; Kaczmarczyk M; Ciechanowski K; Ciechanowicz A; Ostrowski M
Transplant Proc; 2009; 41(1):177-80. PubMed ID: 19249508
[TBL] [Abstract][Full Text] [Related]
32. Treatment of symptomatic hepatic cysts by percutaneous instillation of minocycline hydrochloride.
Yamada N; Shinzawa H; Ukai K; Makino N; Matsuhashi T; Wakabayashi H; Togashi H; Takahashi T
Dig Dis Sci; 1994 Nov; 39(11):2503-9. PubMed ID: 7956621
[TBL] [Abstract][Full Text] [Related]
33. Hypertension in autosomal dominant polycystic kidney disease.
Chapman AB; Stepniakowski K; Rahbari-Oskoui F
Adv Chronic Kidney Dis; 2010 Mar; 17(2):153-63. PubMed ID: 20219618
[TBL] [Abstract][Full Text] [Related]
34. Hypertension and renal injury in experimental polycystic kidney disease.
Kennefick TM; Al-Nimri MA; Oyama TT; Thompson MM; Kelly FJ; Chapman JG; Anderson S
Kidney Int; 1999 Dec; 56(6):2181-90. PubMed ID: 10594794
[TBL] [Abstract][Full Text] [Related]
35. [The relation of hypertension, renal function and cardiovascular events in autosomal dominant polycystic kidney disease].
Idrizi A; Barbullushi M; Strakosha A; Kodra S; Thereska N; Zaimi E; Gjyzari A; Petrela E
G Ital Nefrol; 2007; 24(6):595-9. PubMed ID: 18278763
[TBL] [Abstract][Full Text] [Related]
36. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.
Zafar I; Tao Y; Falk S; McFann K; Schrier RW; Edelstein CL
Am J Physiol Renal Physiol; 2007 Sep; 293(3):F854-9. PubMed ID: 17581927
[TBL] [Abstract][Full Text] [Related]
37. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
[TBL] [Abstract][Full Text] [Related]
38. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report.
Antiga L; Piccinelli M; Fasolini G; Ene-Iordache B; Ondei P; Bruno S; Remuzzi G; Remuzzi A
Clin J Am Soc Nephrol; 2006 Jul; 1(4):754-60. PubMed ID: 17699283
[TBL] [Abstract][Full Text] [Related]
39. Chronic subdural haematoma and arachnoid cyst in autosomal dominant polycystic kidney disease (ADPKD).
Leung GK; Fan YW
J Clin Neurosci; 2005 Sep; 12(7):817-9. PubMed ID: 16150597
[TBL] [Abstract][Full Text] [Related]
40. High-density renal cysts in autosomal dominant polycystic kidney disease demonstrated by CT.
Levine E; Grantham JJ
Radiology; 1985 Feb; 154(2):477-82. PubMed ID: 3966136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
